> 首页 > 产品 > 一抗 > 基因重组 > Anti-NKG2A / CD94 Reference Antibody (monalizumab)

Anti-NKG2A / CD94 Reference Antibody (monalizumab)

Recombinant Antibody

Anti-NKG2A / CD159a Reference Antibody (monalizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
The purity of Anti-NKG2A / CD159a Reference Antibody (monalizumab) is more than 95%, determined by SEC-HPLC.
Human NKG2A / CD159a HEK293 cells were stained with Anti-NKG2A / CD94 Reference Antibody (monalizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.0409 ug/mL.
Anti-NKG2A / CD159a Reference Antibody (monalizumab) FACS Blocking was evaluated using human NKG2A/CD94 HEK293 cells. The IC50 was approximately 0.2162 nM.
Anti-NKG2A / CD159a Reference Antibody (monalizumab) Luciferase Assay was evaluated using Human NKG2A / CD159a HEK293. The EC50 was approximately 0.5236 nM.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P26715
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	145 KDa

Additional Information
Target/Specificity	NKG2A / CD94
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.